Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.
Status:
Completed
Trial end date:
2018-04-17
Target enrollment:
Participant gender:
Summary
Patatin-like phospholipase domain-containing protein-3 (PNPLA3), the transmembrane 6
superfamily member 2 protein (TM6SF2) and membrane bound O-acyltransferase domain containing
7 (MBOAT7) genes are involved in non-alcoholic fatty liver disease (NAFLD) development and
worsening. Following the actual scientific knowledge, some studies have identified the
genetic background surrounding NAFLD, counting up to forty different genetic variants that
seem to exert also a crucial role in the disease evolution, according to the natural history,
until hepatocellular carcinoma onset. However, few data exist regarding their influence on
the treatment response. The aim was to explore the effect of 303 mg of silybin-phospholipids
complex, 10 mg of vitamin-D and 15 mg of vitamin-E twice a day for six months in NAFLD
patients carrying PNPLA3-rs738409, TM6SF2-rs58542926 and MBOAT7-rs641738 genetic variants.
The assessed mutations are independently associated with no response to a silybin/vitamin
D-based therapy and could be useful therapeutic predictive markers in this context.